Bone Disorders

FDA approves Atelvia for osteoporosis

Warner Chilcott announced that the FDA has approved Atelvia (risedronate sodium delayed-release tablets) for the treatment of postmenopausal osteoporosis.

PROLIA (denosumab) 60mg subcutaneous injection by Amgen

Prolia approved for postmenopausal osteoporosis

The FDA has approved Prolia (denosumab, from Amgen) for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.